No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary raynaud phenomenon: A randomized controlled trial

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 3, 2012, Pages 215-221

  Bredie, Sebastian J H ^a   Jong, Miek C ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LOUIS BOLK INSTITUTE   (Netherlands)

Author keywords

EGb 761; Ginkgo biloba; placebo controlled; Raynaud phenomenon

Indexed keywords

GINKGO BILOBA EXTRACT; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSESTHESIA; DYSPNEA; EPISTAXIS; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RAYNAUD PHENOMENON; RIGIDITY; TREATMENT OUTCOME; VASOSPASM;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLANT EXTRACTS; RAYNAUD DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 84858800077     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31823c0bed     Document Type: Article

References (30)

1. Cooke JP, Marshall JM. Mechanisms of Raynaud's disease. Vasc Med. 2005;10:293-307. (Pubitemid 43137279)
2. Raynaud M. On Local Asphyxia and Symmetrical Gangrene of the Extremities. London, United Kingdom: New Sydenham Society; 1862.
3. LeRoy EC, Medsger TA, Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485-488.
4. Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. J Chronic Dis. 1986;39:423-427. (Pubitemid 16044155)
5. Baumhakel M, Bohm M. Recent achievements in the management of Raynaud 's phenomenon. Vasc Health Risk Manag. 2010;6:207-214.
6. Bakst R, Merola JF, Franks AG, Jr, et al. Raynaud 's phenomenon: path-ogenesis and management. J Am Acad Dermatol. 2008;59:633-653.
7. Generini S, Del Rosso A, Pignone A, et al. Current treatment options in Raynaud 's phenomenon. Curr Treat Options Cardiovasc Med. 2003;5: 147-161.
8. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud 's phenomenon: a meta-analysis. Rheumatology (Oxford). 2005; 44:145-150. (Pubitemid 40277393)
9. Participants in the Raynaud 's Treatment Study (RTS). Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med. 2000;160:1101-1108.
10. Corbin DO, Wood DA, Macintyre CC, et al. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud 's phenomenon. Eur Heart J. 1986;7:165-170. (Pubitemid 16114334)
11. Levien TL. Advances in the treatment of Raynaud 's phenomenon. Vasc Health Risk Manag. 2010;6:167-177.
12. Pittler MH, Ernst E. Complementary therapies for peripheral arterial disease: systematic review. Atherosclerosis. 2005;181:1-7. (Pubitemid 40804687)
13. Jung F, Mrowietz C, Kiesewetter H, et al. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers in German. Arzneimittelforschung. 1990;40:589-593. (Pubitemid 20177474)
14. Stucker O, Pons C, Duverger JP, et al. Effect of Ginkgo biloba extract (EGb 761) on the vasospastic response of mouse cutaneous arterioles to platelet activation. Int JMicrocirc Clin Exp. 1997;17:61-66. (Pubitemid 127791834)
15. Koltermann A, Hartkorn A, Koch E, et al. Ginkgo biloba extract EGb 761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci. 2007;64:1715-1722. (Pubitemid 47036943)
16. Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud 's disease: a double-blind placebo-controlled trial. Vasc Med. 2002;7:265-267. (Pubitemid 36469489)
17. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32.
18. Lehmacher W, Wassmer G, Reitmeir P. Procedures for two-sample comparisons with multiple endpoints controlling the experiment wise error rate. Biometrics. 1991;47:511-521.
19. Watson HR, Robb R, Belcher G, et al. Seasonal variation of Raynaud 's phenomenon secondary to systemic sclerosis. J Rheumatol. 1999;26: 1734-1737. (Pubitemid 29367313)
20. Sarkozi J, Bookman AA, Mahon W, et al. Nifedipine in the treatment of idiopathic Raynaud 's syndrome. J Rheumatol. 1986;13:331-336. (Pubitemid 16034587)
21. Choi WS, Choi CJ, Kim KS, et al. To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud 's phenomenon in South Korea; Korean Raynaud study (KOARA study). Clin Rheumatol. 2009;28:553-559.
22. Weinmann S, Roll S, Schwarzbach C, et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010; 10:14.
23. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med. 2000; 108:276-281. (Pubitemid 30110455)
24. Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud 's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009;48:791-795.
25. Benjamin J, Muir T, Briggs K, et al. A case of cerebral haemorrhage-can Ginkgo biloba be implicated? Postgrad Med J. 2001;77:112-113. (Pubitemid 32120982)
26. Gilbert GJ. Ginkgo biloba. Neurology. 1997;48:1137.
27. Matthews MK, Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology. 1998;50:1933-1934.
28. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med. 1997;336:1108. (Pubitemid 27163872)
29. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. 1996;46:1775-1776.
30. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet. 1998;352:36. (Pubitemid 28306571)